Document is current
Any future updates will be listed below
-
Authors
Brugel, M.
Bouché, O.
Kianmanesh, R.
Teuma, L.
Tashkandi, A.
Regimbeau, J. M.
Pessaux, P.
Royer, B.
Rhaiem, R.
Perrenot, C.
Neuzillet, C.
Piardi, T.
Deguelte, S.
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 16 November 2021
First Online: 7 December 2021
Declarations
:
: The institutional review board at Reims University Hospital approved this study. Patients’ verbal consents were collected in accordance with the protocol MR004 from the Commission Nationale de l’Informatique et des Libertés (no. 2206749, 13/09/2018), and followed the French authorities’ requirements.
: Not applicable.
: M Brugel, R Kianmanesh, L Teuma, A Tashkandi, B Royer, R Rhaiem, C Perrenot, T Piardi, S Deguelte: none; O Bouché: speaker honoraria/advisory role for Merck KGaA, Roche Genentech, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Pierre Fabre, Servier outside the submitted work, JM Regimbeau: advisory role for Quantum Robotics outside the submitted work; P Pessaux: orator for Integra and 3M, co-founder of Virtualisurg outside the submitted work; C Neuzillet: consultancy/honoraria: Pierre Fabre, Servier, Roche, AstraZeneca, Bristol-Myers Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, Fresenius Kabi; research funding: Roche; clinical trials: OSE Immunotherapeutics, AstraZeneca, Bristol-Myers Squibb outside the submitted work.
